Brokerages Set Pediatrix Medical Group, Inc. (NYSE:MD) Target Price at $16.10

Pediatrix Medical Group, Inc. (NYSE:MD) has received an average recommendation of “Hold” from the five brokerages that are currently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $16.10.

Several equities research analysts have commented on the company. Jefferies Financial Group boosted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday. Mizuho raised their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. UBS Group lifted their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th.

Insider Transactions at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the transaction, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the transaction, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,208 shares of company stock worth $327,617. Insiders own 2.00% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after acquiring an additional 164,333 shares during the last quarter. Rubric Capital Management LP lifted its holdings in shares of Pediatrix Medical Group by 1.5% in the third quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock valued at $95,907,000 after purchasing an additional 125,000 shares in the last quarter. Boston Partners boosted its position in shares of Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after buying an additional 453,254 shares during the last quarter. Dana Investment Advisors Inc. grew its holdings in Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after buying an additional 455,785 shares in the last quarter. Finally, Brandes Investment Partners LP raised its position in Pediatrix Medical Group by 12.8% in the 2nd quarter. Brandes Investment Partners LP now owns 735,068 shares of the company’s stock valued at $5,438,000 after buying an additional 83,588 shares during the last quarter. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Stock Down 1.8 %

NYSE:MD opened at $15.22 on Monday. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $16.41. The stock’s fifty day simple moving average is $12.38 and its 200-day simple moving average is $9.77. The firm has a market capitalization of $1.31 billion, a P/E ratio of -4.97, a P/E/G ratio of 2.22 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same quarter last year, the firm earned $0.29 EPS. Pediatrix Medical Group’s quarterly revenue was up .9% compared to the same quarter last year. Equities research analysts expect that Pediatrix Medical Group will post 1.25 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.